These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8961239)

  • 1. CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects.
    Vandel P; Bonin B; Vandel S; Sechter D; Bizouard P
    Med Hypotheses; 1996 Dec; 47(6):439-42. PubMed ID: 8961239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
    Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
    Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More data for the CYP2D6 hypothesis?: the in vivo inhibition of CYP2D6 isoenzyme and extrapyramidal symptoms induced by antidepressants in the elderly.
    García-Parajuá P; de Ugarte L; Baca E
    J Clin Psychopharmacol; 2004 Feb; 24(1):111-2. PubMed ID: 14709967
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?
    Vandel P; Haffen E; Vandel S; Bonin B; Sechter D; Bizouard P; Dalery J
    Therapie; 2000; 55(3):349-53. PubMed ID: 10967711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-mediated side effects of psychopharmacological treatment.
    Maurer I; Volz HP
    Arzneimittelforschung; 2001 Oct; 51(10):785-92. PubMed ID: 11715630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tricyclic antidepressant-induced extrapyramidal side effects.
    Vandel P; Bonin B; Leveque E; Sechter D; Bizouard P
    Eur Neuropsychopharmacol; 1997 Aug; 7(3):207-12. PubMed ID: 9213080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
    Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
    Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
    Zourková A; Hadasová E
    Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
    Vandel P
    World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Central motor and extrapyramidal side effects under therapy with antidepressants (author's transl)].
    Böning J
    Fortschr Neurol Psychiatr; 1982 Feb; 50(2):35-47. PubMed ID: 7095714
    [No Abstract]   [Full Text] [Related]  

  • 12. Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly.
    Govoni S; Racchi M; Masoero E; Zamboni M; Ferini-Strambi L
    Mol Psychiatry; 2001 Mar; 6(2):134-42. PubMed ID: 11317214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6-inhibiting drugs and risk of fall injuries after newly initiated antidepressant and antipsychotic therapy in a Swedish, register-based case-crossover study.
    Dahl ML; Leander K; Vikström M; Frumerie C; Nordenmalm S; Möller J; Söderberg-Löfdal K
    Sci Rep; 2021 Mar; 11(1):5796. PubMed ID: 33707555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
    Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
    Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?
    D'Empaire I; Guico-Pabia CJ; Preskorn SH
    J Psychiatr Pract; 2011 Sep; 17(5):330-9. PubMed ID: 21926528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
    Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
    Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
    Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.
    Köhnke MD; Griese EU; Stösser D; Gaertner I; Barth G
    Pharmacopsychiatry; 2002 May; 35(3):116-8. PubMed ID: 12107857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
    Preskorn SH
    J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.